Accordingly, patients with metastatic stage III melanoma tumours had a significantly higher mRNA expression for RAD50, NBS1, MRE11 and ATM as compared to patients with primary melanoma (Figure S7A–D). This evidence concerns the gene RAD50 and melanoma.